Compared side by side

Semaglutide vs efinopegdutide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Semaglutide acts on one receptor, GLP-1; efinopegdutide is a weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease, because glucagon acts on the liver directly. In a 24-week trial, efinopegdutide cut liver fat by about 73%, against 42% on semaglutide 1 mg. Semaglutide is FDA-approved for type 2 diabetes, weight management and MASH, as Ozempic and Wegovy; efinopegdutide isn’t approved anywhere.

Side by side

ComparedSemaglutideEfinopegdutide
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asOzempic, WegovyMK-6024, JNJ-64565111, Efino
What it isA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.A once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease.
How it worksGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.Once-weekly GLP-1 and glucagon receptor co-agonist, the same pair as mazdutide and survodutide, tuned about 2 to 1 toward GLP-1. GLP-1 lowers appetite and weight; glucagon acts on the liver directly and is thought to make it burn more of its stored fat. That is why Merck is developing it for MASH, the inflamed form of fatty liver disease, rather than for weight alone. Investigational; first made by Hanmi Pharmaceutical, then tested by Janssen in obesity, and now with Merck.
Commonly reportedThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.GI side effects during step-ups, and weight loss too. Not approved anywhere.
Studied rangeFDA label: 0.25–2.4 mg, starting dose 0.25 mg.Research range: 4–10 mg, starting dose 2 mg. Studied in research — not a recommendation.
How oftenWeekly SubQWeekly
Half-life~1 week (FDA label)Not reported in an open human PK source; dosed once weekly in all its trials
RouteSubQ injectionSubQ injection
Typical runFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.Used continuously, once weekly, in its trials: 24 to 52 weeks, stepping up every 4 weeks from 2 mg in the MASH trial. No trial has tested stopping it.
EvidenceEstablished: clinical trials or FDA-approved use existsModerate: animal studies + some human data
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis riskNausea, vomiting, diarrhea

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking semaglutide or efinopegdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Semaglutide

  • Day 1–28 · 0.25 mg Gut is adapting
  • Day 29–56 · 0.5 mg Appetite shifts are real now
  • Day 57–112 · 1 mg Clinically useful weight loss kicks in
  • Day 113–140 · 1.7 mg Max submaximal step
  • Day 141–364 · 2.4 mg Full dose — the working dose
  • Day 365+ Plateau territory — new baseline

Every card for semaglutide, with its sources

Efinopegdutide

  • Day 1–28 · 2 mg A gentle first month
  • Day 29–364 · 4 mg Four milligrams
  • Day 57–364 · 7 mg The dose the trial favoured
  • Day 57–364 Weight comes down too
  • Day 85–364 · 10 mg Ten milligrams: more side effects, not more benefit

Every card for efinopegdutide, with its sources

Questions people ask

How long do semaglutide and efinopegdutide last?

The half-life of semaglutide is ~1 week (FDA label). The half-life of efinopegdutide is not reported in an open human PK source; dosed once weekly in all its trials.

How often are semaglutide and efinopegdutide taken?

Semaglutide: weekly SubQ. Route: SubQ injection. Efinopegdutide: weekly. Route: SubQ injection.

How are semaglutide and efinopegdutide dosed in research?

The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for efinopegdutide is 4–10 mg, with a 2 mg starting dose. Studied in research — not a recommendation.

What are the common side effects of semaglutide and efinopegdutide?

For semaglutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk. For efinopegdutide: nausea, vomiting, diarrhea.

Each one in full

Track it in the app

PepVault for iPhone

Taking semaglutide or efinopegdutide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo